On October 18, 2022 Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr metal-free click chemistry (Press release, Synaffix, OCT 18, 2022, View Source [SID1234622093]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Synaffix will obtain exclusive rights to the CliCr technology, to combine with its proprietary ADC platform technology. This further expands the GlycoConnect ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager applications.